Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Sava Technologies raises $36M in Series B led by Ascensia to develop glucose sensor technology eliminating fingerstick testing.
Amount Raised
$36 Million
Round Type
Series B
LondonBiotechnologyHealth CareInvestors
Description
Sava Technologies, a London-based medical device company, has secured $36 million in Series B funding led by Ascensia Diabetes Care, bringing total funding to $68 million. The capital will support development of a microsensor designed to eliminate the need for fingerstick glucose tests, with Ascensia partnering to commercialize and distribute the product in Europe. Founded in 2019 by bioengineers Renato Circi and Rafaël Michali, Sava aims to secure regulatory approval for insulin dosing without fingerstick checks within 18-24 months. The company's microsensors are approximately ten times smaller than conventional continuous glucose monitors, reducing skin disruption.
Fundz sees it the moment Sava Technologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansSava Technologies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.